Merck's stock gets upgraded

A Wall Street investment bank has thrown Merck a bone by upgrading its stock from "neutral" to "outperform," meaning it's poised to achieve better results than other drug companies. Shares were up on the news, as was the mood at HQ. Sure, Merck is beset by generic competition (as are its counterparts), and it has plenty of legal trouble to wrestle with, but it's riding high on a couple of blockbusters, including the asthma and allergy drug Singulair and the hypertension remedy Cozaar. Merck's pipeline of new prospects is heavily populated. Its new HIV drug Isentress is poised for FDA approval this fall, and late-stage trial results are due on its experimental heart attack remedy MK-0524A. Even vaccines are showing financial promise for the company, including RotaTeq, the anti-rotavirus shot, and Zostavax, a shingles vaccine. Gardisil, the HPV preventative, even got a mandate from the governor of Texas.

- check out this article from Forbes for more

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.